-
Anti IPD
Pneumococcal 13
Project in collaboration with Partners
-
Anti IMD
Meningococcal Group ACWY
Project in collaboration with Partners
Meningococcal Group B L8 Endotoxoid
(Concept for Safety Phase I)
Meningococcal Group B L7 Endotoxoid
(Nanostructured VS)
Meningococcal Pentavalent (A,B,C,W,Y)
-
Multidrug Resistance
- Escherichia Coli
- Salmonella Typhi
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
-
Acinetobacter baumannii
-
Nanostructured Vector System for Viral subunit vaccines
- COV-2
- RSV
- Influenza
BiosYnth s.r.l. - P.IVA 00736000522 - Capitale Sociale: € 520.000 I.V.
Developed by